These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 18484781)
1. Cardiotoxicity profile of trastuzumab. Ewer SM; Ewer MS Drug Saf; 2008; 31(6):459-67. PubMed ID: 18484781 [TBL] [Abstract][Full Text] [Related]
2. The cardiac safety of trastuzumab in the treatment of breast cancer. Chien AJ; Rugo HS Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Castrellon AB; Glück S Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789 [TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Perez EA Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950 [TBL] [Abstract][Full Text] [Related]
6. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068 [TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761 [TBL] [Abstract][Full Text] [Related]
8. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083 [TBL] [Abstract][Full Text] [Related]
9. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768 [TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Schneider JW; Chang AY; Rocco TP Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Fiúza M Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637 [TBL] [Abstract][Full Text] [Related]
13. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153 [TBL] [Abstract][Full Text] [Related]
14. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. McKeage K; Perry CM Drugs; 2002; 62(1):209-43. PubMed ID: 11790161 [TBL] [Abstract][Full Text] [Related]
16. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400 [TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750 [TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Suter TM; Cook-Bruns N; Barton C Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418 [TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068 [TBL] [Abstract][Full Text] [Related]
20. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium. Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]